INTERVIEW: Chipscreen CEO Bets Big On Chinese Innovation
This article was originally published in PharmAsia News
When initial funding burned through and co-founders bailed out, Chipscreen CEO Lu Xianping faced the biggest challenge of his career. A firm belief in scientific evidence and an unwavering confidence in China-originated innovation helped him launch chidamide, a true made in China drug for a rare blood cancer, Lu told PharmAsia News in an exclusive interview.
You may also be interested in...
Huya CEO Mireille Gingras On Partnering To Develop Chinese Compounds In The West: An Interview With PharmAsia News
San Diego-based Huya Bioscience partners with Chinese research institutions and companies to identify preclinical and clinical-stage compounds, including traditional Chinese medicines to license for ex-China development. CEO Mireille Gingras recently spoke with PharmAsia News about Huya's partnership efforts in China. Prior to founding Huya, Gingras was founder and chief operating officer of MIR3, a software company developing online treatment programs for neuro-addictive diseases.
BeiGene's BTK inhibitor for leukemia/lymphoma and Sanofi/Genzyme's enzyme replacement therapy for MPS I among novel drugs newly approved in China.
In a key step to prop up traditional Chinese medicines, Beijing has proposed a law that could potentially punish any vocal doubters. The move signals a familiar pattern as China resorts to using old approaches when facing a flurry of new challenges.